SE0103836D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
SE0103836D0
SE0103836D0 SE0103836A SE0103836A SE0103836D0 SE 0103836 D0 SE0103836 D0 SE 0103836D0 SE 0103836 A SE0103836 A SE 0103836A SE 0103836 A SE0103836 A SE 0103836A SE 0103836 D0 SE0103836 D0 SE 0103836D0
Authority
SE
Sweden
Prior art keywords
novel compounds
sup
pharmaceutical compositions
therapy
preparing
Prior art date
Application number
SE0103836A
Other languages
English (en)
Swedish (sv)
Inventor
Timothy Johnson
Michael Stocks
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0103836A priority Critical patent/SE0103836D0/xx
Publication of SE0103836D0 publication Critical patent/SE0103836D0/xx
Priority to TW091132764A priority patent/TW200407297A/zh
Priority to CA002464863A priority patent/CA2464863A1/en
Priority to NZ532755A priority patent/NZ532755A/en
Priority to DK02783941T priority patent/DK1448195T3/da
Priority to DE60215851T priority patent/DE60215851T2/de
Priority to JP2003543594A priority patent/JP4559077B2/ja
Priority to AU2002347741A priority patent/AU2002347741B2/en
Priority to US10/495,711 priority patent/US7129246B2/en
Priority to AT02783941T priority patent/ATE344034T1/de
Priority to SI200230458T priority patent/SI1448195T1/sl
Priority to PL02370855A priority patent/PL370855A1/xx
Priority to IL16169302A priority patent/IL161693A0/xx
Priority to ES02783941T priority patent/ES2274110T3/es
Priority to CN028225171A priority patent/CN1585640B/zh
Priority to PT02783941T priority patent/PT1448195E/pt
Priority to KR10-2004-7007397A priority patent/KR20040058290A/ko
Priority to MXPA04004498A priority patent/MXPA04004498A/es
Priority to BR0214142-6A priority patent/BR0214142A/pt
Priority to RU2004112780/04A priority patent/RU2300525C2/ru
Priority to PCT/SE2002/002057 priority patent/WO2003041707A1/en
Priority to HU0402560A priority patent/HUP0402560A3/hu
Priority to EP02783941A priority patent/EP1448195B1/en
Priority to MYPI20024270A priority patent/MY136430A/en
Priority to ARP020104406A priority patent/AR037534A1/es
Priority to UA20040503316A priority patent/UA77978C2/uk
Priority to CO04043373A priority patent/CO5580747A2/es
Priority to ZA200403682A priority patent/ZA200403682B/xx
Priority to IS7261A priority patent/IS7261A/is
Priority to NO20042155A priority patent/NO20042155L/no
Priority to HK04110069A priority patent/HK1067048A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE0103836A 2001-11-16 2001-11-16 Novel compounds SE0103836D0 (sv)

Priority Applications (31)

Application Number Priority Date Filing Date Title
SE0103836A SE0103836D0 (sv) 2001-11-16 2001-11-16 Novel compounds
TW091132764A TW200407297A (en) 2001-11-16 2002-11-07 Novel compounds
EP02783941A EP1448195B1 (en) 2001-11-16 2002-11-12 N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation
CN028225171A CN1585640B (zh) 2001-11-16 2002-11-12 作为药物组合物的n-金刚烷基甲基衍生物和中间体以及其制备方法
MXPA04004498A MXPA04004498A (es) 2001-11-16 2002-11-12 Derivados de n-adamantilmetil e intermediarios como composiciones farmaceuticas y procesos para su preparacion.
DK02783941T DK1448195T3 (da) 2001-11-16 2002-11-12 N-adamantylmethylderivater og mellemprodukter som farmaceutiske præparater og fremgangsmåde til fremstilling deraf
DE60215851T DE60215851T2 (de) 2001-11-16 2002-11-12 N-adamantylmethyl-derivate und zwischenprodukte als pharmazeutische zusammensetzungen und verfahren zu ihrer herstellung
JP2003543594A JP4559077B2 (ja) 2001-11-16 2002-11-12 医薬組成物としてのｎ−アダマンチルメチル誘導体および中間体、ならびにそれらの製造方法
AU2002347741A AU2002347741B2 (en) 2001-11-16 2002-11-12 N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation
US10/495,711 US7129246B2 (en) 2001-11-16 2002-11-12 N-adamantlmethyl derivatives and intermediates as pharmaceutical compositions and processes for their preparation
AT02783941T ATE344034T1 (de) 2001-11-16 2002-11-12 N-adamantylmethyl-derivate und zwischenprodukte als pharmazeutische zusammensetzungen und verfahren zu ihrer herstellung
SI200230458T SI1448195T1 (sl) 2001-11-16 2002-11-12 N-adamantilmetilni derivati in intermediati kot farmacevtski sestavki in postopki za njihovo pripravo
PL02370855A PL370855A1 (en) 2001-11-16 2002-11-12 N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation
IL16169302A IL161693A0 (en) 2001-11-16 2002-11-12 N-adamantylmethyl derivatives and intermediates as pharmaceutical compositions and processes for their preparation
ES02783941T ES2274110T3 (es) 2001-11-16 2002-11-12 Derivados de n-adamantilmetilo e intermedios como composiciones farmaceuticas y procedimientos para su preparacion.
CA002464863A CA2464863A1 (en) 2001-11-16 2002-11-12 N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation
PT02783941T PT1448195E (pt) 2001-11-16 2002-11-12 Derivados de n-adamantilmetilo e intermediários como composições farmacêuticas e processos para a sua preparação
KR10-2004-7007397A KR20040058290A (ko) 2001-11-16 2002-11-12 제약 조성물로서의 ｎ-아다만틸메틸 유도체 및 중간체 및그의 제조 방법
NZ532755A NZ532755A (en) 2001-11-16 2002-11-12 N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation
BR0214142-6A BR0214142A (pt) 2001-11-16 2002-11-12 Derivados e intermediários de n-adamantilmetila como composições farmacêuticas e processos para sua preparação
RU2004112780/04A RU2300525C2 (ru) 2001-11-16 2002-11-12 Производные и промежуточные соединения n-адамантилметила в качестве фармацевтических композиций и способы их получения
PCT/SE2002/002057 WO2003041707A1 (en) 2001-11-16 2002-11-12 N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation
HU0402560A HUP0402560A3 (en) 2001-11-16 2002-11-12 N-adamantylmethyl derivates, processes for their preparation, pharmaceutical compositions thereof and intermediates
MYPI20024270A MY136430A (en) 2001-11-16 2002-11-14 N-adamantylmethyl derivatives, pharmaceutical compositions containing them and processes for their preparation
ARP020104406A AR037534A1 (es) 2001-11-16 2002-11-15 Derivado de adamantano, su uso en la fabricacion de un medicamento para usar en terapia, composicion farmaceutica, proceso para la preparacion de dicho compuesto y dicha composicion y compuestos intermediarios
UA20040503316A UA77978C2 (en) 2001-11-16 2002-12-11 N-adamantylmethyl derivatives and intermediates, pharmaceutical composition and method for production thereof
CO04043373A CO5580747A2 (es) 2001-11-16 2004-05-11 Derivados e intermediarios de n-adamantilmetilo como composiciones farmaceuticas y procesos para su preparacion
ZA200403682A ZA200403682B (en) 2001-11-16 2004-05-13 N-adamantylmethyl derivatives and intermediates as pharmaceutical composition and processes for their preparation.
IS7261A IS7261A (is) 2001-11-16 2004-05-13 N-adamantýlmetýlafleiður og milliefni sem lyfjablöndur og aðferðir til að framleiða þær
NO20042155A NO20042155L (no) 2001-11-16 2004-05-25 N-adamantylmetylderivater og mellomprodukter som farmasoytiske sammensetninger og fremgangsmater til deres fremstilling
HK04110069A HK1067048A1 (en) 2001-11-16 2004-12-20 N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for theirpreparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0103836A SE0103836D0 (sv) 2001-11-16 2001-11-16 Novel compounds

Publications (1)

Publication Number Publication Date
SE0103836D0 true SE0103836D0 (sv) 2001-11-16

Family

ID=20286020

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0103836A SE0103836D0 (sv) 2001-11-16 2001-11-16 Novel compounds

Country Status (30)

Country Link
US (1) US7129246B2 (es)
EP (1) EP1448195B1 (es)
JP (1) JP4559077B2 (es)
KR (1) KR20040058290A (es)
CN (1) CN1585640B (es)
AR (1) AR037534A1 (es)
AT (1) ATE344034T1 (es)
AU (1) AU2002347741B2 (es)
BR (1) BR0214142A (es)
CA (1) CA2464863A1 (es)
CO (1) CO5580747A2 (es)
DE (1) DE60215851T2 (es)
DK (1) DK1448195T3 (es)
ES (1) ES2274110T3 (es)
HK (1) HK1067048A1 (es)
HU (1) HUP0402560A3 (es)
IL (1) IL161693A0 (es)
IS (1) IS7261A (es)
MX (1) MXPA04004498A (es)
MY (1) MY136430A (es)
NO (1) NO20042155L (es)
NZ (1) NZ532755A (es)
PL (1) PL370855A1 (es)
PT (1) PT1448195E (es)
RU (1) RU2300525C2 (es)
SE (1) SE0103836D0 (es)
TW (1) TW200407297A (es)
UA (1) UA77978C2 (es)
WO (1) WO2003041707A1 (es)
ZA (1) ZA200403682B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
GB0013737D0 (en) 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300480D0 (sv) * 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
EP1644041A1 (en) * 2003-05-29 2006-04-12 AstraZeneca AB A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
TW200507829A (en) * 2003-05-29 2005-03-01 Astrazeneca Ab New combination
WO2004105796A1 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate
GB0312609D0 (en) * 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
KR100554155B1 (ko) * 2003-06-09 2006-02-22 학교법인 포항공과대학교 금속/반도체 나노막대 이종구조를 이용한 전극 구조물 및그 제조 방법
SE0302139D0 (sv) * 2003-07-28 2003-07-28 Astrazeneca Ab Novel compounds
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
SE0402925D0 (sv) * 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
KR20090094336A (ko) 2006-11-27 2009-09-04 하. 룬트벡 아크티에 셀스카브 헤테로아릴 아미드 유도체
CN101679350B (zh) * 2007-03-22 2014-03-12 阿斯利康(瑞典)有限公司 用于治疗炎性疾病的喹啉衍生物
KR20090130109A (ko) 2007-04-10 2009-12-17 하. 룬트벡 아크티에 셀스카브 Ｐ2ｘ7 길항제로서의 헤테로아릴 아미드 유사체
PE20091036A1 (es) 2007-11-30 2009-08-15 Astrazeneca Ab Derivado de quinolina como antagonista del receptor p2x7
CA2719745C (en) 2008-03-25 2016-07-05 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
ATE541832T1 (de) 2009-04-14 2012-02-15 Affectis Pharmaceuticals Ag Neuartige p2x7r-antagonisten und ihre verwendung
CN102858741A (zh) 2010-05-14 2013-01-02 阿费克蒂斯制药股份公司 制备p2x7r拮抗剂的新方法
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
AR087274A1 (es) 2011-07-22 2014-03-12 Actelion Pharmaceuticals Ltd Derivados de amidas heterociclicas como antagonistas de receptores p2x7
NZ628910A (en) 2012-01-20 2016-02-26 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
KR101576235B1 (ko) * 2012-11-30 2015-12-11 한국생명공학연구원 신규한 이치환 아다만틸 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 암 전이 억제용 약학적 조성물
WO2014091415A1 (en) 2012-12-12 2014-06-19 Actelion Pharmaceuticals Ltd Indole carboxamide derivatives as p2x7 receptor antagonists
EP2935211B1 (en) 2012-12-18 2016-11-09 Actelion Pharmaceuticals Ltd. Indole carboxamide derivatives as p2x7 receptor antagonists
US9388198B2 (en) 2013-01-22 2016-07-12 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
CN104918617B (zh) 2013-01-22 2017-05-10 埃科特莱茵药品有限公司 作为p2x7受体拮抗剂的杂环酰胺衍生物
CN104163795B (zh) * 2014-08-19 2016-02-03 四川大学 盐酸烟酰美金刚胺溶剂合物、其制备方法和用途
CN104628615B (zh) * 2015-02-12 2016-04-06 佛山市赛维斯医药科技有限公司 含卤代苯的n-金刚烷酰胺类化合物、其制备方法及其用途
CN104628616B (zh) * 2015-02-12 2016-06-01 佛山市赛维斯医药科技有限公司 含对硝基苯基的n-金刚烷酰胺类化合物、其制备方法及用途
CN104628617B (zh) * 2015-02-12 2016-04-06 佛山市赛维斯医药科技有限公司 N-金刚烷酰胺类葡萄糖激酶活化剂、制备方法及其用途
CN104693084B (zh) * 2015-02-12 2016-03-16 佛山市赛维斯医药科技有限公司 含腈基苯基的n-金刚烷酰胺类化合物、其制备方法及用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3352912A (en) * 1963-07-24 1967-11-14 Du Pont Adamantanes and tricyclo[4. 3. 1. 1 3.8] undecanes
US3471491A (en) * 1967-08-28 1969-10-07 Squibb & Sons Inc Adamantyl-s-triazines
US3464998A (en) * 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
US4027035A (en) * 1968-08-27 1977-05-31 Eli Lilly And Company Therapeutic uses of adamantanealkylamine compounds
GB1274652A (en) * 1968-08-27 1972-05-17 Lilly Industries Ltd Adamantanyl-alkylamine derivatives and their preparation
IL53441A0 (en) * 1977-11-22 1978-01-31 Teva Pharma Methyladamantyl hydrazines their preparation and pharmaceutical compositions containing them
US4751292A (en) * 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
AU5177390A (en) * 1989-03-10 1990-10-09 Idemitsu Kosan Company Limited Pyridine derivatives and their salts, and insecticidal/acaricidal agent containing the same as active ingredient
ES2152989T3 (es) 1993-08-10 2001-02-16 Black James Foundation Ligandos para los receptores de gastrina y cck.
FR2761358B1 (fr) * 1997-03-27 1999-05-07 Adir Nouveaux composes de n-aryl piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
SE9704545D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704544D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
HUP0202214A3 (en) 1999-04-09 2002-12-28 Astrazeneca Ab Adamantane derivatives, preparation and use thereof
GB0013737D0 (en) 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
SE0200920D0 (sv) 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
HUP0402560A3 (en) 2009-03-02
CN1585640A (zh) 2005-02-23
AR037534A1 (es) 2004-11-17
CN1585640B (zh) 2010-10-27
JP2005519028A (ja) 2005-06-30
US20050010052A1 (en) 2005-01-13
US7129246B2 (en) 2006-10-31
DE60215851T2 (de) 2007-05-24
NO20042155L (no) 2004-08-16
ZA200403682B (en) 2005-08-03
HUP0402560A2 (hu) 2005-04-28
NZ532755A (en) 2005-11-25
DE60215851D1 (de) 2006-12-14
MY136430A (en) 2008-10-31
EP1448195A1 (en) 2004-08-25
KR20040058290A (ko) 2004-07-03
RU2300525C2 (ru) 2007-06-10
WO2003041707A1 (en) 2003-05-22
PL370855A1 (en) 2005-05-30
CA2464863A1 (en) 2003-05-22
EP1448195B1 (en) 2006-11-02
IL161693A0 (en) 2004-09-27
TW200407297A (en) 2004-05-16
UA77978C2 (en) 2007-02-15
ATE344034T1 (de) 2006-11-15
CO5580747A2 (es) 2005-11-30
IS7261A (is) 2004-05-13
JP4559077B2 (ja) 2010-10-06
PT1448195E (pt) 2007-02-28
DK1448195T3 (da) 2007-02-12
ES2274110T3 (es) 2007-05-16
RU2004112780A (ru) 2005-10-10
HK1067048A1 (en) 2005-04-01
AU2002347741B2 (en) 2008-03-13
MXPA04004498A (es) 2004-08-11
BR0214142A (pt) 2004-09-14

Similar Documents

Publication Publication Date Title
SE0103836D0 (sv) Novel compounds
ATE316083T1 (de) Adamantanderivate
SE0300480D0 (sv) Novel compounds
IS6658A (is) Ný efnasambönd
SE0104140D0 (sv) Novel Compounds
SE0200920D0 (sv) Novel compounds
HK1048990A1 (en) Novel compounds.
SE9902987D0 (sv) Novel compounds
MY128924A (en) Novel compounds
SE0202539D0 (sv) Compounds
SE9904505D0 (sv) Novel compounds
SE0302139D0 (sv) Novel compounds
MXPA04000756A (es) Nuevos compuestos.
SE9901875D0 (sv) Novel compounds
TW200604197A (en) New compounds
SE0101038D0 (sv) Novel compounds
SE0402925D0 (sv) Novel Compounds
GB0120461D0 (en) Novel compounds
GB0104050D0 (en) Chemical compounds
SE0102716D0 (sv) Novel compounds
SE0303280D0 (sv) Novel compounds
SE0401763D0 (sv) Compounds
SE0202693D0 (sv) Compounds
SE0202692D0 (sv) Compounds
SE0302755D0 (sv) Novel compounds